All results
2 results for sbrt lung non daily treatment
-
NIMBLE
This study will assess whether switching participants who have benefitted from mepolizumab or benralizumab to GSK3511294 (Depemokimab) is non-inferior to…
- Ages
- 12 Years - N/A
- Sexes
- All
-
GSK Nimble
This study will assess whether switching participants who have benefitted from mepolizumab or benralizumab to GSK3511294 (Depemokimab) is non-inferior to…
- Ages
- 12 Years - N/A
- Sexes
- All